Figure 1

Time between infusions. The percentages of patients with the indicated mean infusion intervals during the post-loading period are shown among those with at least 4 infusions in the infliximab cohorts (first line infliximab n = 506; subsequent line infliximab n = 136) and the abatacept cohort (n = 344), and the percentage of patients with the indicated mean time between infusion courses among those with at least 2 courses is shown for the rituximab cohort (n = 139). Dashed lines indicate the current product label intervals (the course interval for rituximab was added to the label after the study period).